This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace (TALK) delivered earnings and revenue surprises of 50% and 2.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
Talkspace, Inc. (TALK) concluded the recent trading session at $3.13, signifying a -0.95% move from its prior day's close.
Why the Market Dipped But Talkspace, Inc. (TALK) Gained Today
by Zacks Equity Research
In the most recent trading session, Talkspace, Inc. (TALK) closed at $3.09, indicating a +0.65% shift from the previous trading day.
Is Talkspace (TALK) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Talkspace (TALK) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Talkspace, Inc. (TALK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Talkspace, Inc. (TALK) closed at $2.97, marking a +1.02% move from the previous day.
3 Medical Info Systems Stocks to Buy as Industry Improves
by Urmimala Biswas
A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.
What Makes Talkspace, Inc. (TALK) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Talkspace, Inc. (TALK) have what it takes to be a top stock pick for momentum investors? Let's find out.
3 Medical Info Systems Stocks to Buy as Industry Rebounds
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like Clover Health Investments (CLOV), Talkspace (TALK) and P3 Health Partners (PIII) are expected to gain from the new normal trends.
Talkspace, Inc. (TALK) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Talkspace, Inc. (TALK) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks Industry Outlook Highlights P3 Health Partners, Talkspace and Augmedix
by Zacks Equity Research
P3 Health Partners, Talkspace and Augmedix are pat of the Zacks Industry Outlook article.
3 Medical Info Systems Stocks to Buy as Industry Trends Improve
by Urmimala Biswas
Zacks Medical Info Systems industry stocks like P3 Health Partners (PIII), Talkspace (TALK) and Augmedix (AUGX) are expected to gain from the new normal trends.
Talkspace, Inc. (TALK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 50% and 7.20%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Talkspace, Inc. (TALK) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
Talkspace, Inc. (TALK) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 28.57% and 10.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 27.27% and 4.10%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Upgraded to Buy: Here's Why
by Zacks Equity Research
Talkspace, Inc. (TALK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Talkspace, Inc. (TALK) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of 15.38% and 2.16%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
AllScripts Healthcare (MDRX) Q3 Earnings Top Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of 21.05% and 0.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Nextgen Healthcare (NXGN) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Nextgen Healthcare (NXGN) delivered earnings and revenue surprises of 4.17% and 1.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Talkspace, Inc. (TALK) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Talkspace, Inc. (TALK) delivered earnings and revenue surprises of -15.38% and 4.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Privia Health (PRVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Privia Health (PRVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies (AXNX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axonics (AXNX) delivered earnings and revenue surprises of 17.54% and 16.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?